Feasibility Study of a Modified XELOX Adjuvant Chemotherapy for High-Recurrence Risk Patients With Operated Stage III Colon Cancer

• Váldodahkkit: Jianhong Peng (Dahkki), Weihao Li (Dahkki), Wenhua Fan (Dahkki), Wenhao Zhou (Dahkki), Ying Zhu (Dahkki), Xueying Li (Dahkki), Zhizhong Pan (Dahkki), Xiaoping Lin (Dahkki), Junzhong Lin (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2020-09-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

BackgroundOur previous study reported the favorable efficacy and good tolerance associated with a modified XELOX adjuvant chemotherapy with eight cycles of capecitabine and six cycles of oxaliplatin for operated stage III colon cancer. The current study aimed to confirm the feasibility of modified X...